EGFR and non-small cell lung carcinoma: Previous study reported that gefitinib had quite variable growth-suppressive effects on different EGFR-expressing cells, and the kinase domain of EGFR subtypes may alter drug responsiveness in NSCLC (Chen et al., 2006).